More on UGNE
Financials
News
Click line-items for a historical chart and %
| Product sales | 0 |
| Royalties | 84.96K |
| Licensing revenue | 262.69K |
| Development fees and other | 203.57K |
| Tarsa revenue | |
| [Revenues] | 613.77K |
| Research and development | 850.52K |
| Cost of goods sold | 1.64M |
| General and administrative | 1.98M |
| Unallocated facility expenses | 529.25K |
| Inventory reserve | |
| Severance and other related expense | |
| [OperatingExpenses] | 5.97M |
| Operating loss | -5.36M |
| Gain (loss) on change in fair value of embedded conversion feature | |
| Debt issuance cost | |
| Interest and other income | 10.54K |
| Interest expense | -4.52M |
| (Loss) gain from investment in China joint venture | 0 |
| Loss from investment in Tarsa | |
| Loss before income taxes | 1.98M |
| Income tax benefit from sale of state tax benefit | 0 |
| Net loss | 1.98M |
| Loss per share – basic and diluted: Net loss per share (in Dollars per share) | -0.01 |
| Weighted average number of shares outstanding - basic and diluted (in Shares) | 508M |
